Course page
Chairperson

Aleksandar Sekulic, MD, PhD
Assistant Professor of Dermatology
Vice Chair, Department of Dermatology
Mayo Clinic Arizona
Scottsdale, Arizona


Dr. Aleksandar Sekulic is Assistant Professor of Dermatology and Vice Chair in the Department of Dermatology at Mayo Clinic Arizona in Scottsdale. His clinical practice focuses on cutaneous oncology including malignant melanoma and other pigmented lesions, epidermal neoplasms, and cutaneous T-cell lymphoma. Dr. Sekulic’s research is centered on developing translational approaches for the study of genomics in skin diseases, identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation as it relates to human skin disease.

Dr. Sekulic has served as a teacher and mentor for numerous residents and students and is a recipient of the Excellence in Teaching Recognition Award at Mayo Medical School. He most recently was honored to receive the 2012 Gerstner Family Foundation Career Development Award in Individualized Medicine. He has given international, national, and regional presentations and has co-authored several articles, book chapters, abstracts, and letters that have been published in peer-reviewed journals including The New England Journal of Medicine, The American Journal of Surgery, Journal of Cancer, Cancer Prevention Research, Oncologist, British Journal of Dermatology, and Mayo Clinic Proceedings. His research has been funded by the National Cancer Institute and other organizations.

Dr. Sekulic earned an MD degree from the University of Zagreb School of Medicine in Croatia. He attended Mayo Graduate School where he earned a PhD degree in immunology and completed a residency in dermatology. He holds professional memberships in societies such as the American Association for Cancer Research, American Association for the Advancement of Science, American Medical Association, Medical Dermatology Society, and the Minnesota Medical Association.

COI Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Aleksandar Sekulic, MD, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS; Deborah Middleton, MS; Jocelyn Timko, BS, and Ronald Viggiani, MD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Faculty 

Patricia M. LoRusso, DO
Professor of Medicine
Associate Director of Innovative Medicine
Yale Cancer Center
New Haven, Connecticut


Dr. Patricia M. LoRusso is a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center. She has more than 25 years of experience in medical oncology, drug development, and early phase clinical trials.

Dr. LoRusso is President of Women in Cancer Research and is an American Association for Cancer Research (AACR) board member. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as Director of the phase 1 clinical trials program and of the Eisenberg Center for Experimental Therapeutics.

Dr. LoRusso served as co-chair of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program Investigational Drug Steering Committee; she also served on the scientific committee of the AACR, the education and scientific committees of the American Society of Clinical Oncology, and numerous peer-reviewed study sections. Dr. LoRusso has garnered numerous awards, including the 1999 Heroes of Breast Cancer Award, 2004 Bennett J. Cohen Educational Leadership Award for Medical Research, 2008 NCI Michaele C. Christian Oncology Development Lectureship and Award, the 2014 Targeted Anticancer Therapies Honorary Award, and will receive the 2014 Michigan State University Distinguished Alumni Award. She was recently honored as one of the 2014 Massachusetts General Hospital Cancer Center’s “One Hundred” individuals and organizations recognized for their dedication in making a difference in the fight against cancer. Dr. LoRusso is a former editor of Investigational New Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has written and published more than 200 articles on cancer research in peer-reviewed journals, and wrote multiple book chapters.

Dr. LoRusso earned a DO degree from Michigan State University in East Lansing.

COI Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Patricia M. LoRusso, DO, reported a financial interest/relationship or affiliation in the form of Consulting fee: Astex Pharmaceuticals Inc.; Genentech, Inc.; Pfizer, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS; Deborah Middleton, MS; Jocelyn Timko, BS, and Ronald Viggiani, MD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Faculty 

Vernon K. Sondak, MD
Chair, Department of Cutaneous Oncology
Director of Surgical Education
H. Lee Moffitt Cancer Center & Research Institute
Professor, Departments of Oncologic Sciences and Surgery
University of South Florida Morsani College of Medicine
Tampa, Florida


Dr. Vernon K. Sondak is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine. His research interests include surgical treatment of malignant melanoma in adults and children; surgical treatment of Merkel cell carcinoma, desmoid tumors, and cutaneous soft-tissue sarcomas, including dermatofibrosarcoma protuberans; adjuvant and neoadjuvant therapy of melanoma; and evaluation of new therapies for patients with localized or disseminated melanoma. Dr. Sondak has also been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy to the staging of melanoma and Merkel cell carcinoma. He is actively involved in ongoing analyses to determine which patients with thin melanoma are most likely to benefit from sentinel node biopsy, as well as which patients with sentinel node metastases are most likely to have further metastases identified in other regional lymph nodes.

Dr. Sondak is the author or coauthor of over 335 articles in peer-reviewed publications, 176 abstracts, and 8 books and 67 book chapters.

Dr. Sondak earned an MD degree from Boston University School of Medicine. He completed an internship and residency in general surgery and a fellowship in surgical oncology at the UCLA School of Medicine in Los Angeles, California.

COI Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Vernon K. Sondak, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards: Amgen, Inc.; Genentech/Roche; MabVax Therapeutics; Merck & Co., Inc.; Navidea Biopharmaceuticals; Data and safety monitoring board memberOncoSec Medical; Polynoma LLC; Provectus Biopharmaceuticals; Bristol-Myers Squibb Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS; Deborah Middleton, MS; Jocelyn Timko, BS, and Ronald Viggiani, MD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.